Other

Medinova Medical Consulting Gmbh

Jorg Kreuter

Bernhard A Sabel

Andreas Zimmer

Christian Noe

Renad N Alyautdin

Hans-Peter Zobel

Frank Stieneker

Serap Atmaca-Abdel Aziz

Dimitri A Karkevich

The medicament in particulate form has one or more anionic or partially anionic active substances bound to a carrier material. The carrier material includes particulate copolymer or homopolymer of acrylic acid or acrylic acid ester or methacrylic acid esters. The carrier further includes oxygen in the ester group, a branched or unbranched alkyl chain with 2-10 carbon atoms, --NR.sub.2 where R represents H and lower alkyl chains in any combination, and H or a lower alkyl chain. The grain size distribution of the carrier is 10-1000 nm.

Medicament in particulate form

A novel method of delivering drugs and diagnostics across the blood-brain barrier or blood-nerve barrier is disclosed. Drugs or diagnostic agents are incorporated into nanoparticles which have been fabricated in conventional ways. These nanoparticles are then coated with additional surfactant and given to the body of animals or humans. This allows drugs or diagnostic agents to cross the blood-brain barrier (bbb) to achieve one or more of the following benefits: (1) reducing the dose of a therapeutic drug or diagnostic agent which, when given peripherally, maintains the biological or diagnostic potency in the nervous system, (2) allowing drugs that normally do not cross the bbb to penetrate into the nervous system, and (3) reducing the peripheral side effects by increasing the relative amount of the drug reaching the brain.

Drug targeting to the nervous system by nanoparticles

Growing community of inventors

Bad Homburg, Germany

Jorg Kreuter